IDO1 and renal cell carcinoma: While combined IDO1/TDO inhibitors are currently in early Phase trials (NCT03208959), our results suggest that, in RCC at least, the kynurenine pathway is much more widely dysregulated and may require further downstream modulation in addition to IDO inhibition.